JPMorgan raised the firm’s price target on TG Therapeutics to $34 from $28 and keeps an Overweight rating on the shares. The company reported a strong quarter driven the Briumvi Launch, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics price target raised to $37.50 from $26 at Ladenburg
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- TG Therapeutics price target raised to $34 from $28 at H.C. Wainwright
- TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- TG Therapeutics reports Q1 EPS (28c), consensus (37c)